JAK Inhibitor Misses Endpoint in Safety Study. Now What? Pfizer announced results Wednesday from its FDA-mandated postmarketing safety study of tofacitinib (Xeljanz), and they don't bode well for the drug and possibly others in its class. https://t.co/EPVdAdPP37 https://t.co/Box5NaxsKV